On the morning of September 11, 2026, China’s National Healthcare Security Administration (NHSA) held a symposium on surgical robotics.

Representatives from seven domestic and international surgical robotics companies attended the meeting, including Sinovation Medical, MicroPort MedBot, Medtronic, IntuFosun, Edge Medical, TINAVI and Stryker. Representatives from five hospitals — Guangdong Provincial People’s Hospital, Peking University People’s Hospital, Beijing Tiantan Hospital, Beijing Jishuitan Hospital and Beijing Tongren Hospital — also participated.

The meeting sent another clear policy signal.

Over the past year, China’s healthcare security system has already established several mechanisms closely related to the commercialization of surgical robots: pricing items have created a formal route for hospitals to charge for robot-assisted procedures; DRG/DIP 3.0 has introduced separate groupings for certain robot-assisted surgeries; and work on real-world value assessment and data standards is also moving forward.

At this symposium, the NHSA released another notable direction: supporting real-world comprehensive healthcare security value assessment projects and exploring how surgical robots should be evaluated based on their actual clinical value.

China’s surgical robotics industry is therefore moving from the stage of gaining “access” toward the next stage of demonstrating “value.”

Over the Past Year, Healthcare Security Policy Has Addressed Two Key Barriers to Surgical Robot Commercialization

To understand the significance of the September 11 meeting, it is useful to first look at what has already changed.

For surgical robots to enter hospitals, two basic questions need to be addressed.

The first is a charging pathway.

In January 2026, the NHSA issued the Guidelines for Establishing Medical Service Pricing Items for Surgical and Treatment Assistance Operations (Trial).

The guidelines standardized 37 medical service pricing items, five surcharge items and one extension item, covering technologies including 3D printing, image-guided procedures, energy devices, surgical robots and remote surgery.

For surgical robots, three pricing categories were established based on their level of participation in a procedure: navigation, assisted execution and precision execution.

This effectively created a nationally standardized pricing framework for robot-assisted surgery, giving hospitals a clearer basis for charging for surgical robotic services.

After the national framework was released, local implementation began to follow.

For example, after Hunan Province issued its pricing standards in May 2026, the charges for robotic assistance were linked to the robot’s role in surgery. Navigation, assisted execution and precision execution were assigned different charging levels.

The specific amounts are less important than the structure itself: robot-assisted surgery now has a formal pricing mechanism rather than being left without a defined charging route.

The second is DRG payment.

Previously, even if hospitals were able to charge for robotic surgery, another problem remained.

If a robot-assisted procedure and a conventional procedure were placed in the same DRG group, but the robotic procedure involved higher equipment and consumable costs, hospitals could face greater cost pressure under a fixed payment standard.

DRG/DIP 3.0 has started to address this issue.

The latest grouping framework has introduced dedicated groups for a number of robot-assisted procedures. Under DRG, nine surgical robot-related groups have been established across specialties including orthopedics, urology and gynecology. DIP has also introduced related groups for certain procedures.

This does not automatically mean that reimbursement will be higher.

But it creates a basis for distinguishing the resource consumption of robot-assisted surgery from conventional procedures rather than combining them under the same payment category.

So the first two steps are now increasingly clear: pricing rules determine whether hospitals can charge for robotic assistance, while DRG/DIP grouping determines how robot-assisted procedures are recognized within the payment system.

Real-World Value Assessment: A Network of 79 “Trusted Evaluation Sites” Has Been Established

In January 2026, Peking University People’s Hospital and 78 other medical institutions jointly established the first network of trusted evaluation sites for real-world comprehensive healthcare security value assessment.

The network is intended to support standardized real-world evidence generation.

For the surgical robotics industry, the implications are relatively direct.

Future healthcare security evaluation may not focus only on purchase price or the cost of a single procedure. It may increasingly examine whether the use of a surgical robot produces measurable improvements in areas such as clinical outcomes, resource utilization and overall healthcare value.

This matters because surgical robotics companies have traditionally concentrated heavily on technical indicators: accuracy, stability, number of robotic arms, degrees of freedom, applicable procedures and other product specifications.

But once reimbursement increasingly incorporates value assessment, companies may also need to answer another question:

What healthcare value does this surgical robot actually create?

This could involve outcomes such as complications, hospital length of stay, recovery, resource use and other measurable indicators.

The establishment of a trusted evaluation network provides infrastructure for collecting and evaluating this type of evidence.

NHSA Pushes Back Against the Idea That “More Expensive Surgery Is Better”

Another important point emerged from the September 11 symposium.

The discussion did not treat surgical robots simply as expensive equipment whose value should be justified by higher prices.

Instead, participants emphasized that surgical robotics is still in an early stage of innovation and development.

The technology has advantages in areas such as precision, stability, resistance to fatigue, reduction of certain human errors, multiple degrees of freedom and multi-angle visualization. At the same time, challenges remain in price, operator training, supporting instruments and consumables, force feedback, visualization and applicable clinical scenarios.

This is important for the industry.

The policy direction is not that surgical robots should become more expensive because they are technologically advanced.

The more relevant question is whether they can demonstrate corresponding clinical and healthcare value.

For companies, simply emphasizing the price of the robot, technical specifications or the concept of “high-end medical equipment” will be increasingly insufficient.

The future discussion will likely center more on whether a system reduces complications, shortens learning curves, improves surgical quality, reduces resource consumption or creates other measurable benefits.

Data Standards: A Policy Signal That May Be Underestimated

The September 11 symposium also mentioned another issue that could become increasingly important: data standards.

Participants discussed supporting the development of standards for surgical robot positioning and navigation data and human-machine interaction data, with the longer-term aim of supporting wider use, faster technology iteration and potentially cooperation among robotic systems from different manufacturers.

This may look like a technical issue, but it also has policy implications.

At present, different surgical robotics systems often use their own motion-control data, procedure data, navigation data and interaction data formats.

If surgical robots continue to incorporate AI, automated recognition, intelligent execution and other functions, the lack of standardized data could become an obstacle to broader development.

Healthcare security authorities are therefore not only discussing how to pay for surgical robots.

They are also beginning to pay attention to the data infrastructure behind how surgical robots are used, evaluated and iterated.

For manufacturers, this may eventually involve issues such as data security, knowledge and ownership rights, hospital responsibilities and certification requirements.

Remote Surgery Is Being Given a Public Healthcare Security Role

Remote surgery was also discussed at the symposium.

The NHSA has already created a dedicated medical service pricing item for remote surgical assistance, allowing medical institutions to charge for qualified remote surgical services under the pricing framework.

The September 11 discussion further emphasized the potential role of remote robotic surgery in areas such as border regions, remote islands, natural disasters and emergency response.

This gives remote surgery a broader policy context.

It is not being viewed only as a demonstration of advanced robotic technology, but also as a potential means of extending access to specialist medical resources.

From an industry perspective, this could expand the application boundaries of surgical robotics.

But it also raises additional requirements involving network stability, clinical safety, remote operational reliability and supporting infrastructure.

The Participant List Itself Is Informative

The companies attending the symposium covered a broad range of surgical robotics categories.

Participants included Sinovation Medical, MicroPort MedBot, Medtronic, IntuFosun, Edge Medical, TINAVI and Stryker.

The five participating hospitals represented clinical disciplines including orthopedics, neurosurgery, urology, ophthalmology and other areas.

The composition of the meeting suggests that policy discussions are no longer focused on one specific type of surgical robot.

Surgical robotics is increasingly being considered as a broader category of medical service technology that could span multiple clinical specialties.

Future healthcare security evaluation and payment mechanisms may therefore need to account for the substantial differences between different robotic systems and procedures.

What Does This Mean for Companies?

Taken together, the September 11 meeting provides several relatively clear signals.

For surgical robotics companies, market access is becoming more complex.

Registration remains essential, but companies increasingly also need to understand Market Access, HEOR (Health Economics and Outcomes Research), medical service pricing items, DRG/DIP grouping and real-world value assessment.

If a company begins considering these issues only after receiving regulatory approval, commercialization may face additional obstacles.

Companies will also need stronger capabilities in generating clinical and economic evidence.

In the future, answering the question “What problem does this surgical robot solve?” may no longer be enough.

Companies may increasingly need to demonstrate how much value it creates, whether that value can be measured, and whether the healthcare system is willing to pay for it.

Data quality, comparative evidence and cost-control capabilities may all become important factors influencing market access and payment.

For sales, medical affairs and market access teams, KPIs may also gradually extend beyond installation numbers toward long-term utilization and measurable clinical value.

If the equipment is installed but remains underused, that could become an increasingly difficult commercialization model to sustain.